MMP2 and neoplasm: By conjugating doxorubicin with a trastuzumab epitope and an MMP-2-sensitive peptide linker (Fmoc-KPLGLAGCRGDK), the hydrogel is susceptible to degradation by MMP-2, allowing targeted drug release in the tumor microenvironment.